TSX Exchange Symbol: RVX
CALGARY, Aug. 21 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is
pleased to announce that it will host a live teleconference on August 25, 2008
at 11:00 am MDT to provide a corporate update of the Company. Following the
presentation there will be a live question and answer session.
The webcast can be accessed at the following link:
Participants can also dial in for the conference call:
Dial information is as follows:
North American Toll Free Dial In: 1-800-319-4610
International Dial In: +1-604-638-5340
The webcast will be available on the Resverlogix website for replay for a
period of 10 days after the event.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com; Website: www.resverlogix.com